May 16, 2022 Proactive Investors: Vyant Bio Ends 1Q with $16.4M in Cash to Fund Small Molecule Therapeutics Research for Neurological Diseases
Apr 1, 2022 Parkinson’s News Today: Vyant Bio, OrganoTherapeutics Will Use Organoids for New Therapies
Mar 30, 2022 Proactive Investors: Vyant Bio Ends 2021 with $20.6M in Cash as It Sharpens Focus on Novel Drug Discovery
Mar 29, 2022 Proactive Investors: Vyant Bio Enters Collaboration with OrganoTherapeutics to Find Treatments for Parkinson's Disease
Mar 10, 2022 Proactive Investors: Vyant Bio Fires Up Its Drug Discovery Engine to Speed Up Novel Therapeutics for Brain Diseases
Mar 1, 2022 Proactive Investors: Vyant Bio Says It is ‘Well-Positioned’ to Discover Novel Therapeutics to Treat Neurological Diseases
Nov 11, 2021 Proactive Investors: Vyant Bio Reports Total Revenue of $1.5M in 3Q 2021, Shares Strategic Updates
